A Phase 1b, Open-Label Study to Evaluate the Safety of AMG 479 in Combination with Gemcitabine as First-line Therapy for Metastatic Pancreatic Cancer
Phase 1
- Conditions
- Advanced solid tumor
- Registration Number
- JPRN-jRCT2080221160
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Major inclusion criteria include the following:
1)Subjects must have histologically or cytologically documented and confirmed metastatic adenocarcinoma of the pancreas
2)Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
3)Men or women over 20 years old of age
Exclusion Criteria
Major exclusion criteria include the following:
1)Islet cell, acinar cell carcinoma, non-adenocarcinoma, (eg, lymphoma, sarcoma, etc), adenocarcinoma originated from biliary tree or cystadenocarcinoma
2)Known history of central nervous system metastases
3)Internal or external biliary drain
4)A history of other malignancies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method